RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $425

Benzinga Newsdesk www.benzinga.com Positive 93.1%

Neg 0% Neu 0% Pos 93.1%

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $423 to $425.